Clinigen Hosts Unlicensed Medicines Satellite Symposium At 22nd Congress Of EAHP
Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, announces that its Idis GA division is holding a satellite symposium today on Access to Unlicensed Medicines as part of the 22nd Congress of European Association of Hospital Pharmacists (EAHP), taking place in Cannes, France.
Clinigen’s symposium runs from 9:00-10:30am on Thursday 23rd March 2017 in the Theatre Debussy in Palais des Festivals et des Congrès de Cannes.
The event is being chaired by Bernard Naughton, from Oxford University Hospitals NHS Foundation Trust alongside other speakers Mike Isles, Executive Director for the European Alliance for Access to Safe Medicines and Clinigen’s Chief Medical Officer, Ivo Timmermans.
The symposium will provide expert insight and opinions on the patient-critical and evolving issue of unlicensed medicines. The speakers’ presentations will cover the changing landscape of unlicensed medicines; provide pointers on the challenges facing hospital pharmacists when searching for an ethical and timely supply of medicines, and how pharmacists can maintain an optimal service for all stakeholders: patients, physicians and policy-makers.
The symposium will include the following presentations:
• A History of Access to Medicines; 30 Years On – Ivo Timmermans
• Fulfilling Patient Needs; A View From The Sharp End – Bernard Naughton
• Falsified Medicines: The Role of the Pharmacist in Raising Patient Awareness – Mike Isles
There will also be an interactive Q&A held at the end of the event.
A summary report will be made available on Clinigen’s website at www.clinigengroup.com shortly after the event.
- ENDS -
Issued for and on behalf of Clinigen Group by Instinctif Partners.
For more information please contact:
Clinigen Group plc
Shaun Chilton, Group Chief Executive Officer
Tel: +44 (0) 1283 495010
Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Tom Ballard (Corporate Broking)
RBC Capital Markets - Joint Broker
Tel: +44 (0) 20 7653 4000
Marcus Jackson / Elliot Thomas / Jack Wood
Instinctif Partners
Tel: +44 (0) 20 7457 2020
Melanie Toyne-Sewell /Dr Samantha Cheung / Alex Shaw
Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time and is focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.
The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).
Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital medicines.
For more information, please visit www.clinigengroup.com
Clinigen’s symposium runs from 9:00-10:30am on Thursday 23rd March 2017 in the Theatre Debussy in Palais des Festivals et des Congrès de Cannes.
The event is being chaired by Bernard Naughton, from Oxford University Hospitals NHS Foundation Trust alongside other speakers Mike Isles, Executive Director for the European Alliance for Access to Safe Medicines and Clinigen’s Chief Medical Officer, Ivo Timmermans.
The symposium will provide expert insight and opinions on the patient-critical and evolving issue of unlicensed medicines. The speakers’ presentations will cover the changing landscape of unlicensed medicines; provide pointers on the challenges facing hospital pharmacists when searching for an ethical and timely supply of medicines, and how pharmacists can maintain an optimal service for all stakeholders: patients, physicians and policy-makers.
The symposium will include the following presentations:
• A History of Access to Medicines; 30 Years On – Ivo Timmermans
• Fulfilling Patient Needs; A View From The Sharp End – Bernard Naughton
• Falsified Medicines: The Role of the Pharmacist in Raising Patient Awareness – Mike Isles
There will also be an interactive Q&A held at the end of the event.
A summary report will be made available on Clinigen’s website at www.clinigengroup.com shortly after the event.
- ENDS -
Issued for and on behalf of Clinigen Group by Instinctif Partners.
For more information please contact:
Clinigen Group plc
Shaun Chilton, Group Chief Executive Officer
Tel: +44 (0) 1283 495010
Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Tom Ballard (Corporate Broking)
RBC Capital Markets - Joint Broker
Tel: +44 (0) 20 7653 4000
Marcus Jackson / Elliot Thomas / Jack Wood
Instinctif Partners
Tel: +44 (0) 20 7457 2020
Melanie Toyne-Sewell /Dr Samantha Cheung / Alex Shaw
Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time and is focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.
The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).
Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital medicines.
For more information, please visit www.clinigengroup.com